0001387131-22-008516.txt : 20220809 0001387131-22-008516.hdr.sgml : 20220809 20220809091553 ACCESSION NUMBER: 0001387131-22-008516 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-254975 FILM NUMBER: 221146855 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 424B5 1 tnxp-424b5_080922.htm PROSPECTUS SUPPLEMENT

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-254975

Registration No. 333-251500

Registration No. 333-237610

 

PROSPECTUS SUPPLEMENT

(To Prospectus Dated May 5, 2021, January 4, 2021 and April 17, 2020)

$320,000,000

Common Stock

 

 

This prospectus supplement amends and supplements the information in the prospectus, dated April 8, 2020, filed as a part of our registration statement on Form S-3 (File No. 333-237610), as previously supplemented by our prospectus supplements dated April 8, 2020, September 4, 2020, or the 2020 Prospectus, the information in the prospectus, dated January 4, 2021, filed as part of our registration statement on Form S-3 (File No. 333-251500), as previously supplemented by our prospectus supplement dated April 16, 2021, together with the 2020 Prospectus, the 2020/2021 Prospectuses, the prospectus, dated May 5, 2021, filed as a part of our registration statement on Form S-3 (File No. 333-254975), as previously supplemented by our prospectus supplement dated December 29, 2021, and together with the 2020/2021 Prospectuses, the Prior Prospectuses. This prospectus supplement should be read in conjunction with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.

Under the Prior Prospectuses, we collectively registered up to $240,000,000 of our Common Stock, $0.001 par value per share, for offer and sale pursuant to a Sales Agreement, dated April 8, 2020, or the Sales Agreement, between us and A.G.P./Alliance Global Partners. From April 8, 2020 through the date of this prospectus supplement, we sold an aggregate of 31.2 million shares of our Common Stock for an aggregate purchase price of $212.8 million under the Prior Prospectuses. As of the date of this prospectus supplement, we are increasing the aggregate amount of Common Stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $320,000,000 of our Common Stock for sale under the Sales Agreement, including the shares of Common Stock previously sold, or $107.2 million from and after the date hereof.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

 

 

A.G.P.

The date of this prospectus supplement is August 9, 2022. 

  

 

 

 

GRAPHIC 2 tnxp-001.gif GRAPHIC begin 644 tnxp-001.gif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